The Globe and Mail reports in its Friday, March 1, edition that BMO Capital analyst Thanos Moschopoulos has reaffirmed his "market perform" recommendation for MDA. The Globe's David Leeder writes in the Eye On Equities column that Mr. Moschopoulos raised his share target to $15 from $13. Analysts on average target the shares at $15.79. Mr. Moschopoulos says in a note: "We like many aspects of the story and view the stock's valuation as undemanding relative to its growth, backlog and pipeline. However, its leverage and near-term FCF profile keep us on the sidelines." The Globe reported on Nov. 12 and Aug. 18 that Citi analyst Jason Gursky had reaffirmed his "neutral" recommendation for MDA. The shares could then be had for $10.25 and $12.04. The Globe reported on Aug. 15 that RBC Capital analyst Ken Herbert had reiterated his "outperform" recommendation for MDA. The shares were then worth $10.47. The Globe reported on Jan. 23 that Scotia Capital analyst Konark Gupta was sticking with his "sector outperform" recommendation for MDA. The shares were then going for $11.41.